By Paloma Baviera (Gynaecologist – Reg. No. 030310335). Article updated and medically reviewed on 27/10/2026 by Alejandro Olloqui Escalona (Licensed Gynecologist – 282867126).
According to data from the World Health Organization, approximately 604,000 new cases of cervical cancer were diagnosed worldwide in 2024, making it the fifth most common cancer among women. Despite its incidence, it is a largely preventable disease through HPV vaccination, screening tests and appropriate treatment of precancerous lesions.
The cervix consists of the lower part of the uterus, which is connected to the vagina. Cervical cancer occurs when malignant cells proliferate in the cervix, which is generally linked to a persistent infection caused by the human papillomavirus (HPV). While cervical cancer can be a serious disease, it is critical to stress that prevention is possible, as is early detection, which is what we are concerned with today.

It is estimated that 80% of the population will at some point in their lives contract a strain of human papillomavirus. In this context, it is worth noting that HPV vaccines are effective tools to prevent the development of high-risk strains that can lead to cervical lesions.
HPV vaccination is particularly effective when given before sexual activity begins, as it can prevent infections caused by the virus types covered by the vaccine. Although it may also be recommended for certain people who have already been exposed to HPV, the vaccine does not eliminate existing infections or treat any lesions they may have caused.
Likewise, it is essential to follow routine gynaecological check-ups, as a smear can detect abnormalities or dysplasias whose follow-up or treatment will have a much more favourable prognosis, compared to that of a late diagnosis.
Early detection is essential for preventing cervical cancer, as it makes it possible to identify cellular changes before they develop into malignant lesions. In Spain, the screening programme is aimed at women aged 25 to 65, although the tests used and how often they are carried out vary according to age and HPV vaccination history.
According to recommendations from Spain’s Ministry of Health, women aged 25 to 29 who are not adequately protected by vaccination should have a cervical smear every three years, while screening for vaccinated women may begin at age 30, depending on how the programme is implemented. Women aged 30 to 65 are recommended to have a high-risk HPV test every five years if the result is negative. These checks are still necessary for vaccinated women, as the vaccine does not protect against every type of the virus. Follow-up should be tailored to the individual in higher-risk situations.
While the human papillomavirus does not appear to be linked to reproductive difficulties, other sexually transmitted infections that tend to occur at the same time can indeed lead to reproductive difficulties. In the case of chlamydia, for example, fallopian tube disorders are common.
On the other hand, just as we at IVF-Life aim to raise awareness of cervical cancer, we also see it as crucial to do so in terms of reproductive health. Middle-aged women – when the prevalence of cervical cancer is higher – may consider undergoing fertility preservation treatment, in order to be able to become mothers once they recover. As specialists in complex cases and cases dependent on a multidisciplinary approach, at IVF-Life we also offer reproductive solutions to those patients who have not been able to freeze their eggs.
Cervical cancer is a disease that should not only be remembered today, but of which society rather needs to be fully aware, empathising with women who receive such a diagnosis and with all those who, by receiving valuable information regarding their gynaecological health, can prevent it. Whatever your situation, the most important thing is for you to know that, today and always, we are at your disposal to give you the support you need and the good news you deserve.
Jie Wu, Qianyun Jin, Yunmeng Zhang, Yuting Ji, Jingjing Li, Xiaomin Liu, Hongyuan Duan, Zhuowei Feng, Ya Liu, Yacong Zhang, Zhangyan Lyu, Lei Yang, Yubei Huang.
Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022.
.
2025;
322-329
Estudio epidemiológico basado en los datos de GLOBOCAN 2022 que analiza la incidencia y mortalidad del cáncer de cuello uterino a escala mundial, su evolución temporal y las previsiones futuras:
https://pubmed.ncbi.nlm.nih.gov/40693230/
Jiayao Lei, Alexander Ploner, K. Miriam Elfström, Jiangrong Wang, Adam Roth, Fang Fang, Karin Sundström, Joakim Dillner, Pär Sparén.
HPV Vaccination and the Risk of Invasive Cervical Cancer.
.
2020;
1340-1348
Estudio poblacional realizado en Suecia sobre la asociación entre la vacunación frente al virus del papiloma humano y la reducción del riesgo de cáncer de cuello uterino invasivo:
https://pubmed.ncbi.nlm.nih.gov/32997908/
World Health Organization (WHO).
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.
.
2021;
Guía de la Organización Mundial de la Salud sobre las estrategias de cribado y tratamiento de las lesiones precancerosas del cuello uterino:
https://pubmed.ncbi.nlm.nih.gov/34314129/
Paddy Ssentongo, Jennifer S. McCall-Hosenfeld, William A. Calo, Jennifer Moss, Eugene J. Lengerich, Vernon M. Chinchilli, Djibril M. Ba.
Association of human papillomavirus vaccination with cervical cancer screening: A systematic review and meta-analysis.
.
2022;
e29329
Revisión sistemática y metaanálisis que estudia la relación entre la vacunación frente al VPH y la participación en programas de cribado del cáncer de cuello uterino:
https://pubmed.ncbi.nlm.nih.gov/35839062/